Evidence map›Paper›PMID 41704603›Full record

ArticleFrontiers in oncology2026

Spectral discrimination of pediatric SF188 and adult glioblastoma stem cells by deep learning-enhanced Raman profiling.

Lennard M Wurm, Björn Fischer, Volker Neuschmelting, Roland Goldbrunner, Roland S Croner, Michal W Jagielski, Dominik Laue, Wolfgang Ertel, Michael C Hacker, Jakub Dybaś and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lennard M WurmDepartment of Traumatology and Reconstructive Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Björn FischerHeinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutics and Biopharmaceutics, Düsseldorf, Germany.
Volker NeuschmeltingDepartment of Neurosurgery, University Hospital Cologne, Cologne, Germany.
Roland GoldbrunnerDepartment of Neurosurgery, University Hospital Cologne, Cologne, Germany.
Roland S CronerDepartment of Molecular and Experimental Surgery, Clinic of General- Visceral-, Vascular and Transplantation Surgery, University Hospital Magdeburg and Medical Faculty Otto-von-Guericke University, Magdeburg, Germany.
Michal W JagielskiDepartment of Traumatology and Reconstructive Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Dominik LaueDepartment of Traumatology and Reconstructive Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Wolfgang ErtelDepartment of Traumatology and Reconstructive Surgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
Michael C HackerHeinrich Heine University Düsseldorf, Faculty of Mathematics and Natural Sciences, Institute of Pharmaceutics and Biopharmaceutics, Düsseldorf, Germany.
Jakub DybaśJagiellonian Center for Experimental Therapeutics, Jagiellonian University, Krakow, Poland.
Ulf D KahlertDepartment of Molecular and Experimental Surgery, Clinic of General- Visceral-, Vascular and Transplantation Surgery, University Hospital Magdeburg and Medical Faculty Otto-von-Guericke University, Magdeburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pediatric and adult glioblastomas (GBM) represent biologically distinct entities requiring age-tailored therapeutic strategies. However, rapid and non-invasive methods to distinguish these molecular subtypes remain an unmet clinical need. This study evaluates the potential of confocal Raman spectroscopy combined with deep learning as a label-free diagnostic tool to differentiate pediatric from adult GBM based on intrinsic biochemical fingerprints. Methods: We acquired n=1,382 Raman spectra from a cohort of six patient-derived GBM neurosphere cell lines, comprising a pediatric model (SF188) and five adult-origin lines. A multilayer perceptron (MLP) neural network was trained to classify spectra by age group. To ensure rigorous validation and generalizability, performance was assessed on a strictly held-out external test set (20% of data), completely excluded from model optimization. Results: The deep learning model successfully differentiated pediatric from adult GBM signatures with an overall accuracy of 83.6% and an ROC AUC of 0.855 on the independent test set. Spectral analysis revealed distinct vibrational modes, highlighting significant variations in lipid, protein, and nucleic acid content between age groups. Notably, the model achieved a high sensitivity for the pediatric phenotype (91.4% identification rate) . Conclusion: This proof-of-concept study demonstrates that Raman spectroscopy, augmented by deep learning, can identify age-related molecular variations in GBM without extrinsic labeling. By capturing the unique biochemical landscape of pediatric versus adult tumors, this approach lays the foundation for rapid, automated, and objective diagnostic workflows in precision neuro-oncology.

Indexed as

artificial intelligencedeep learningglioblastoma stem cellslabel-free diagnosticsmolecular fingerprintingpediatric glioblastomaprecision neuro-oncologyraman spectroscopy

Identifiers

PMID41704603
PMCPMC12907151

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.